Nuvilex - NVLX

Nuvilex (NVLX)
Coverage: March 1, 2013 - March 1, 2014
Featured: March 1, 2013

Latest Newsletter Editions

spacer
Fri, Oct 17, 2014 @ 07:10 am
Hedge Fund Managers- Drowning At Their High Water Marks It seems like we might have had the capitulation sell off this week, with...
Mon, Jul 21, 2014 @ 06:07 am
Nuvilex (NVLX): Shutting Them Up It's been the only thing worth covering in July-It's been radio silence from Staffing 360 (STAF...
Sun, Jul 13, 2014 @ 08:07 am
Nuvilex (NVXL): A Tradeable Bottom? Well, it's July and we're in the middle of the summer doldrums. Microcap stocks are exceptionally...
Fri, May 30, 2014 @ 09:05 am
Nuvilex (NVLX): Don't Be Fooled By Quiet Trading It's been a rather quiet week on the trading front for Nuvilex (NVLX), but it's anything but quiet on the corporate front. It's...
Thu, May 1, 2014 @ 09:05 am
Nuvilex (NVLX): Proving My Theory Today The last edition I published on Nuvilex (NVLX) back on April 19th suggested we had finally...

Click Here For More Newsletters on NVLX

spacer

Latest Blog Entries

spacer

Quote Data

spacer
Last Trade: 0.253 Bid: 0.0000
Last Size: 20,800 Ask: 0.0000
Trade Time: 3:59pm Bid x Ask Size: N/A
Change: down arrow -0.0088 (-3.36%) Day's Range: 0.25 - 0.27
Prev Close: 0.2618 52wk Range: 0.10 - 0.62
Open: 0.2610 P/E (ttm): N/A
Volume: 1,049,499 EPS (ttm): -0.038
spacer [Chart]

Business Summary

spacer

Disclosure

spacer
MarketBtye LLC was formerly paid a fee of $10,000 and 1 million newly issued restricted shares of Nuvilex by the company for six months of coverage. The 6 months has expired. On November 1, 2013, MarketByte LLC entered into a consulting agreement with Nuvilex to cover the company for an additional 6 months and received 300,00 newly issued restricted shares. MarketByte LLC currently holds no shares of Nuvilex, and has received $83,155.83 in proceed from sales of NVLX in 2014. At present, MarketByte LLC has no contractual obligation to provide coverage of Nuvilex. Therefore, there are no conflicts of interest.

Recent News Headlines

spacer
Nuvilex, Inc. Moves Closer to "Bio-Artificial Pancreas" Diabetes Treatment With License for Insulin-Producing Cells
Tue, 21 Oct 2014 13:00:00 GMT
[Marketwired] - Nuvilex, Inc. has carefully mapped out its plan to develop a diabetes treatment using the Cell-in-a-Box® platform technology. It started in November 2013 when the company acquired the exclusive worldwide ...
Nuvilex Contracts With University of Veterinary Medicine in Vienna to Conduct Preclinical Studies on the Use of Cell-in-a Box(R) to Develop Diabetes Treatment
Mon, 20 Oct 2014 13:00:00 GMT
[GlobeNewswire] - SILVER SPRING, Md. -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company developing cell and gene therapy solutions for the treatment of diseases, announced today that it has entered into ...
Nuvilex Secures Worldwide License for Insulin-Producing Cells From University of Technology, Sydney, for Use in Developing Diabetes Treatment
Thu, 16 Oct 2014 13:00:00 GMT
[GlobeNewswire] - SILVER SPRING, Md. -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company developing cell and gene therapy solutions for the treatment of diseases, announced today that it has entered into ...
Nuvilex's Cancer Treatment Obtaining FDA Orphan Drug Status Would Make Company Attractive Big Pharma Target
Tue, 14 Oct 2014 13:00:00 GMT
[Marketwired] - Nuvilex, Inc. has officially introduced its advanced pancreatic cancer treatment to the U.S. Food and Drug Administration in an application asking the agency to grant orphan drug status to its Cell-in-a-Box®/ifosfamide......
Nuvilex Applies to FDA for Orphan Drug Designation for Its Cell-in-a-Box(R) Treatment for Pancreatic Cancer
Mon, 13 Oct 2014 13:00:00 GMT
[GlobeNewswire] - SILVER SPRING, Md. -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company developing cell therapy solutions for the treatment of diseases, announced today that it has submitted an application ...
Nuvilex Appoints Dr. Matthias Lohr as Chairman of Scientific Advisory Board
Mon, 06 Oct 2014 13:00:00 GMT
[GlobeNewswire] - SILVER SPRING, Md. -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that noted European gastroenterologist ...
NUVILEX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Office
Fri, 03 Oct 2014 21:15:49 GMT
Nuvilex Announces Strategic Changes to Leadership Team and Appoints Prof. Dr. Walter H. Gunzburg as Chief Scientific Officer
Wed, 01 Oct 2014 13:00:00 GMT
[GlobeNewswire] - SILVER SPRING, Md. -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that Kenneth L. Waggoner, the Chief ...
NUVILEX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Office
Thu, 25 Sep 2014 13:07:45 GMT
Nuvilex's Partner, Austrianova, Publishes Scientific Review Article Emphasizing Use of Cell-in-a-Box(R) for Treatment of Diabetes
Mon, 22 Sep 2014 13:00:00 GMT
[GlobeNewswire] - SILVER SPRING, Md. -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that its partner, Austrianova, ...
NUVILEX, INC. Financials
Fri, 19 Sep 2014 17:04:09 GMT
Nuvilex Updates Shareholders on Recent Activities and Discusses Future Plans for Development of Treatments for Cancer and Diabetes
Thu, 18 Sep 2014 13:24:49 GMT
[GlobeNewswire] - SILVER SPRING, Md. -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell and gene therapy solutions for the treatment of diseases, today provides its shareholders with an ...
NUVILEX, INC. Files SEC form 10-Q, Quarterly Report
Mon, 15 Sep 2014 12:24:01 GMT
Cannabis Support on the Rise as Nuvilex and mCig Move Higher
Mon, 08 Sep 2014 16:00:00 GMT
[Accesswire] - WHITEFISH, MT / September 8, 2014 / Cannabis stocks moved largely lower over the past week amid ongoing profit taking following the industry’s run-up over the past year. Top gainers for the week included ...
Nuvilex's Partner, Austrianova, Receives Prestigious Emerging Enterprises 2014 Best Innovation Award in Singapore
Fri, 05 Sep 2014 17:22:08 GMT
[GlobeNewswire] - SILVER SPRING, Md. -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, reported today that its ...
Nuvilex Submits Application for Orphan Drug Designation to the European Medicines Agency for Its Cell-in-a-Box(R) Treatment for Pancreatic Cancer
Tue, 02 Sep 2014 13:00:00 GMT
[GlobeNewswire] - SILVER SPRING, Md. -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it ...
Nuvilex Begins Preclinical Studies With Translational Drug Development to Determine if Nuvilex's Unique Cancer Treatment Can Slow Accumulation of Malignant Ascites Fluid
Wed, 20 Aug 2014 13:00:00 GMT
[GlobeNewswire] - SILVER SPRING, Md. -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that studies ...
Nuvilex Announces Publication of Combined Results of the Initial Phase 1/2 Clinical Trial and a Second Phase 2 Clinical Trial of the Cell-in-a-Box(R) Plus Ifosfamide Combination in Patients With Advanced, Inoperable Pancreatic Cancer
Thu, 14 Aug 2014 13:00:00 GMT
[GlobeNewswire] - SILVER SPRING, Md. -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that its ...
Nuvilex Provides Update on Status of Preclinical Studies at Translational Drug Development
Wed, 13 Aug 2014 13:00:00 GMT
[GlobeNewswire] - SILVER SPRING, Md. -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it ...
Nuvilex Announces That Dr. Richard M. Hyslop Will Present at the ACS Annual Meeting on "Sustainable, Green Chemistry and Medicine: Targeted Cannabinoid-Based Chemotherapy Utilizing Cell-in-a-Box(R) Live Cell Encapsulation Technology."
Mon, 04 Aug 2014 13:45:50 GMT
[GlobeNewswire] - SILVER SPRING, Md. -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that Dr. ...